ACIU
AC ImmuneยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ACIU Profile
Ac Immune Sa
A biotech company that develops therapeutic and diagnostic products for Alzheimer's disease and other neurodegenerative disorders
Biological Technology
02/13/2003
09/23/2016
NASDAQ Stock Exchange
172
12-31
Common stock
EPFL INNOVATION PARK, Building B, 1015 Lausanne, Switzerland
--
AC Immune SA was first incorporated in Basel on February 13, 2003 as a limited liability company and was later incorporated in June 2021 under the laws of the State of Delaware. AC Immune SA is a leading clinical-stage biopharmaceutical company dedicated to pioneering the field of precision medicine in neurodegenerative diseases. Leveraging two proprietary technology platforms, Supra Antigen and Morphomer, the company has built a comprehensive pipeline of first-in-class or best-in-class drug candidates covering multiple treatment models for both existing and emerging neurodegenerative diseases. The company is currently advancing 16 therapeutic and diagnostic programs, seven of which are undergoing clinical trials for five different types of misfolded pathological proteins associated with Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases.
